ZBIO Stock Forecast & Price Target

Zenas BioPharma is a fundamentally strong company with a promising pipeline of innovative immunology-based therapies. The company's obexelimab has shown positive results in a Phase 3 trial for treatment of IgG4-RD, with a targeted PDUFA date of May 2027. The company's financial position is also strong, with a cash runway through 2029. Positive data from ongoing trials in SLE and multiple sclerosis could potentially act as near-term catalysts for the stock, and the company has a strong leadership team in place for its entry into commercialization. Our valuation and target price for the stock reflect the company's potential for success in these areas, with potential for significant upside. However, there are also risks involved, including potential competition and the company's need for continued funding to support its operations and development programs.

Zenas BioPharma is facing significant losses, with a $111.50MM net loss in 2Q26, and increasing expenses of $62.9MM for R&D and $15.7MM for G&A. Despite near-term potential catalysts like the Phase II SunStone SLE readout and the ongoing IND-enabling studies for ZB022 (oral, brain-penetrant, TYK2-JH2 inhibitor) and ZB014 (HLE, anti-CD19 and FcγRIIb mAb), their current cash position of $673.9MM may not be enough to sustain operations beyond 2Q29, even with additional funding from FDA approval for obexelimab in IgG4-RD and ATM proceeds. Without significant revenue in the near future, Zenas BioPharma may struggle to maintain solvency.